Aura Biosciences (AURA) EBT (2020 - 2026)

Aura Biosciences (AURA) has 7 years of EBT data on file, last reported at -$33.7 million in Q1 2026.

• Quarterly EBT fell 22.61% year-over-year to -$33.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.4 million (up 94.31% YoY) and the FY2025 annual result came in at $828000.0, up 100.95% from the prior year.
• EBT declined to -$33.7 million in Q1 2026, from $81.4 million in the prior quarter.
• In the past five years, EBT ranged from a high of $81.4 million in Q4 2025 to a low of -$74.3 million in Q1 2022.
• A 5-year average of -$22.9 million and a median of -$22.0 million in 2023 frame the typical range for EBT.
• Annual changes were most pronounced in 2022 — EBT tumbled 1135.3% — and 2025, when it soared 415.25%.
• Tracing AURA's EBT over 5 years: stood at -$18.4 million in 2022, then decreased by 19.66% to -$22.0 million in 2023, then decreased by 17.35% to -$25.8 million in 2024, then soared by 415.25% to $81.4 million in 2025, then sank by 141.39% to -$33.7 million in 2026.
• The last three EBT figures came in at -$33.7 million (Q1 2026), $81.4 million (Q4 2025), and -$26.1 million (Q3 2025), per Business Quant data.